Abstract 261P
Background
RD following NACT in TNBC is associated with poor prognosis. However, significant heterogeneity exists within the biology of the RD, and genomic subtyping may enable a more accurate prognostic classification. We already reported the predictive and prognostic value of baseline TNBCtype. Here, we focus on the evolution of TNBCtype after NACT and its prognostic value.
Methods
We present a prospective cohort of stage I-III TNBC patients from 10 hospitals across Spain and Peru, treated with 6 cycles of NACT with carboplatin and docetaxel (NCT01560663). Response was evaluated according to the Symmans Residual Cancer Burden score (RCB). RNAseq was performed on the basal biopsy and the RD following NACT. The TNBCtype classification was done on the TNBCtype online tool.
Results
Paired RNAseq and TNBCtype subtypes from pre- and post-NACT was available for 74 patients. 64.9% of the patients had RCB-2, 29.7% RCB-3 and 5.4% were not evaluable for the RCB classification. Baseline TNBCtype distribution was: BL1 25.7%, BL2 13.5%, LAR 17.6%, M 37.8% and 4 patients were considered as ER+. TNBCtype distribution after NACT was 20.3% BL1, 20.3% BL2, 18.9% M, 18.9% LAR and 21.6% ER+. However, correlation between pre- and post-NACT subtyping was poor, with 55.4% of the samples changing their subtype. Changes occurred within all the subtypes, although tumors initially classified as LAR were the most stable (76.9% concordance), as opposed to M and BL1 (32.1% and 36.8%). Intrinsic subtypes were highly concordant, with only 13.5% changes and most of these changes between non-basal subtypes. With a median follow-up of 55 months, there were 21 distant recurrences and 18 deaths. Post-NACT BL1 and M patients showed the worse long-term survival, with 5y DRFS of 65% and 62.5% as compared to 86.2% and 77.9% for BL2 and LAR. Table: 261P
5y BC EFS | 5y BC DRFS | 5y OS | |
BL1 | 46.7% | 65.0% | 70.0% |
BL2 | 86.2% | 86.2% | 82.5% |
LAR | 53.0% | 77.9% | 81.3% |
M | 56.3% | 62.5% | 67.5% |
Conclusions
TNBCtype significantly differs after exposure to NACT and subtyping of the RD enables a more accurate prognostic classification.
Clinical trial identification
NCT01560663.
Editorial acknowledgement
Legal entity responsible for the study
Hospital General Universitario Gregorio Marañon.
Funding
Instituto de Salud Carlos III.
Disclosure
I. Echavarria Diaz-Guardamino: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, AstraZeneca, Pierre Fabre, Lilly, Gilead; Financial Interests, Personal, Advisory Board: Daichi Sankyo, Lilly. S. Lopez-Tarruella Cobo: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly, Gilead, GSK, Roche, Pierre Fabre, Seagen, Menarini_Stemline, Gebro Pharma, Veracyte, MSD; Financial Interests, Personal, Invited Speaker: Lilly; Non-Financial Interests, Member of Board of Directors: GEICAM, SEOM. Y. Jerez Gilarranz: Financial Interests, Personal, Invited Speaker: Daichii, Novartis, roche, pfizer. F. Moreno Anton: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Gilead; Financial Interests, Institutional, Research Grant: pfizer. T. Massarrah: Financial Interests, Personal, Advisory Board: GSK, Novartis. B. Herrero Lopez: Financial Interests, Personal, Invited Speaker: Roche, Novartis, Pharmamar, Eisai, AstraZeneca, Daichii Sankyo, Pfizer, Teva, Kiowa Kirin, GSK, Gilead. C. Bueno Muiño: Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, AstraZeneca, GSK, Lilly; Financial Interests, Personal, Advisory Board: Pfizer. M. Martin Jimenez: Financial Interests, Personal, Advisory Board: Astrazeneca, Lilly, Roche/Genentech, Daiichi Sankyo, Menarinio-Stemline; Financial Interests, Personal, Invited Speaker: Pfizer, Astrazeneca, Lilly, Novartis, Roche/Genentech; Financial Interests, Institutional, Research Grant: Novartis, Roche, Puma; Non-Financial Interests, Member of Board of Directors: TRIO; Non-Financial Interests, Leadership Role: GEICAM; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Advisory Board: SEOM. All other authors have declared no conflicts of interest.
Resources from the same session
364P - Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Presenter: Eva Ciruelos
Session: Poster session 14
365P - Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Mafalda Oliveira
Session: Poster session 14
366P - Exploring the benefit of combining paclitaxel with capivasertib treatment in PI3K/AKT/PTEN-altered and non-altered TNBC preclinical models
Presenter: Cath Eberlein
Session: Poster session 14
367P - Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer
Presenter: Ezra Rosen
Session: Poster session 14
368P - Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
Presenter: Qiufan Zheng
Session: Poster session 14
370P - A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Presenter: Pin Zhang
Session: Poster session 14
371P - Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
Presenter: Shusen Wang
Session: Poster session 14